BioMarin Reaches New 52-Week High (BMRN)

NEW YORK ( TheStreet) -- BioMarin Pharmaceuticals (Nasdaq: BMRN) hit a new 52-week high Monday as it is currently trading at $42.38, above its previous 52-week high of $42.37 with two million shares traded as of 1:45 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.

BioMarin has a market cap of $4.81 billion and is part of the health care sector and drugs industry. Shares are up 18.6% year to date as of the close of trading on Friday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.

TheStreet Ratings rates BioMarin as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full BioMarin Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.